logo
logo

Lucid Appoints Danielle Scelfo As Senior Vice President, Market Access & Government Affairs

Sep 16, 2025•5 days ago

Position

Senior Vice President

Company

Lucid Diagnostics

Danielle Scelfo
New YorkBiotechnology

Description

Lucid Diagnostics has announced the appointment of Danielle Scelfo as Senior Vice President, Market Access & Government Affairs. Ms. Scelfo will leverage her extensive experience to expand market access and reimbursement efforts for Lucid's EsoGuard test as the company aims for Medicare coverage.

Company Information

Company

Lucid Diagnostics

Location

360 MADISON AVENUE

New York, New York, United States

About

Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients.

Related People

Sign in to view contact details

Sign in to view contact details

Sign in to view contact details

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months